Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 4 102 M
EBIT 2016 990 M
Net income 2016 553 M
Debt 2016 3 615 M
Yield 2016 1,71%
Sales 2017 4 296 M
EBIT 2017 1 071 M
Net income 2017 622 M
Debt 2017 3 758 M
Yield 2017 1,88%
P/E ratio 2016 23,85
P/E ratio 2017 21,31
EV / Sales2016 3,87x
EV / Sales2017 3,73x
Capitalization 12 245 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
01/11 GRIFOLS : acuerda con Hologic la compra de su participación en la unidad de diag..
01/10 GRIFOLS : to Acquire Hologic Blood Donor Screening Unit
2016 GRIFOLS : Hologic sells blood-screening business to Grifols for $1.85 million
2016 Spanish shares gain 1.58% to close at 9,331 points
2016 HOLOGIC : sells blood screening unit to Spanish company for $1.8 billion
2016 GRIFOLS : Spain's Grifols plans to refinance debt in first quarter 2017 after Ho..
2016 GRIFOLS : agreed to acquire Hologic’s share of NAT donor screening unit fo..
2016 GRIFOLS : to buy Hologic's stake in blood screening JV for $1.85 billion
2016 GRIFOLS : Therapeutics Assigned Patent
2016 GRIFOLS SA : ex-dividend day for interim dividend
More news
Sector news : Biopharmaceuticals
01:40pDJELI LILLY AND : to Buy Migraine Drug Developer CoLucid Pharmaceuticals
12:08p Drugmakers in Davos shift focus to chronic diseases of poor
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
More sector news : Biopharmaceuticals
News from SeekingAlpha
2016 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 21,4 €
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Director
Víctor Grifols Roura Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%13 078
BIOGEN INC-0.20%61 576
CSL LIMITED0.48%34 131
ALEXION PHARMACEUTICAL..10.58%30 298
BIOMARIN PHARMACEUTICA..2.86%14 655
GRIFOLS SA1.59%13 078
More Results